Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06591273
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-09-07
Brief Title:
Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis A Single-arm Clinical Trial
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis A Single-arm Clinical Trial
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to learn if Infliximab Biosimilar Remsima works to treat moderate to severe plaque Psoriasis in adults It will also learn about the safety of the drug The main questions it aims to answer are
Does Infliximab-dyyb Biosimilar Remsima works to treat moderate to severe plaque Psoriasis in adults in reducing disease severity and relapses What medical problems do participants have when taking Remsima
Participants will
be injected Infliximab Biosimilar Remsima weekly for 4 weeks and then fortnightly till 24 weeks They will be followed for efficacy and safety and lab tests at week 4 14 24 and 52
Does Infliximab-dyyb Biosimilar Remsima works to treat moderate to severe plaque Psoriasis in adults in reducing disease severity and relapses What medical problems do participants have when taking Remsima
Participants will
be injected Infliximab Biosimilar Remsima weekly for 4 weeks and then fortnightly till 24 weeks They will be followed for efficacy and safety and lab tests at week 4 14 24 and 52
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None